Hyderabad: Even as loss of contract production orders, hike in energy costs, rising inflation and mounting debts have impacted the Indian pharma industry, Biocon has said that the “regulatory underst

Bengaluru: Bengaluru-headquartered biotechnology company Biocon on Saturday announced the launch of a biological drug researched, developed and manufactured in the country to treat chronic plaque pso

Biotechnology major Biocon has reported a 12.49 per cent rise in consolidated net profit to Rs 78.80 crore during the first quarter ended June 30, 2012, on robust performance across business verticals

Bengaluru-based Biocon is planning to forge partnerships as well as leverage existing alliances to augment the access and penetration of its biosimilar molecules.

"We are investing in augmentin

Biocon chief Kiran Mazumdar Shaw on Tuesday suggested that the government should focus on developing energy infrastructure in the state. Addressing a press conference, she said that a lot of industri

An expected licencing income helped Biocon, India's top-listed biotechnology company, post better-than-expected quarterly profit and lift its shares more than 4 per cent, but it said the global busine

Biocon and US drug major Pfizer on Tuesday called off USD 350 million global alliance to commercialise the Bangalore-based firm's biosimilar versions of insulin and insulin analog products.

"The comp

Biocon Ltd, India top biotechnology company, reported a 4 per cent drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered oppor

India's leading biotech firm Biocon Ltd posted net profit of Rs.89 crore for the second quarter (July-Sep) of this fiscal (2010-11), registering a 20 percent year-on-year (YoY) growth.

In a regulator